NOVA — Nova Mentis Life Science Share Price
0.000.00%
Last trade - 00:00- CA$1.48m
- CA$1.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 0.01 | 0.01 | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 27th, 2004
- Public Since
- September 22nd, 2006
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 148,318,660
- Address
- 700-838 West Hasting Street, VANCOUVER, V6C 0A6
- Web
- https://www.novamentis.ca/
- Phone
- +1 7788190244
- Auditors
- Kreston GTA LLP
Upcoming Events for NOVA
Q3 2024 Nova Mentis Life Science Corp Earnings Release
Similar to NOVA
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Alpha Cognition
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
FAQ
What is the Nova Mentis Life Science share price?
As of Today at 16:25 UTC, shares in Nova Mentis Life Science are trading at CA$0.02. This share price information is delayed by 15 minutes.
How has the Nova Mentis Life Science share price performed this year?
Shares in Nova Mentis Life Science last closed at CA$0.02 and the price had moved by -50% over the past 365 days. In terms of relative price strength the Nova Mentis Life Science share price has underperformed the Toronto Stock Exchange 300 Composite Index by -54.96% over the past year.
What are the analyst and broker recommendations for Nova Mentis Life Science?
There is no consensus recommendation for this security.
What is the Nova Mentis Life Science dividend yield?
Nova Mentis Life Science does not currently pay a dividend.
Does Nova Mentis Life Science pay a dividend?
Nova Mentis Life Science does not currently pay a dividend.
When does Nova Mentis Life Science next pay dividends?
Nova Mentis Life Science does not currently pay a dividend.
How do I buy Nova Mentis Life Science shares?
To buy shares in Nova Mentis Life Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nova Mentis Life Science?
As of the previous close price of CA$0.02, shares in Nova Mentis Life Science had a market capitalisation of CA$2.97m.
Where are Nova Mentis Life Science shares listed?
Here are the trading details for Nova Mentis Life Science:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: NOVA
What kind of share is Nova Mentis Life Science?
Based on an overall assessment of its quality, value and momentum Nova Mentis Life Science is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nova Mentis Life Science share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Nova Mentis Life Science share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nova Mentis Life Science. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +30%.
As of the last closing price of CA$0.02, shares in Nova Mentis Life Science were trading -19.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nova Mentis Life Science PE Ratio?
The Nova Mentis Life Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nova Mentis Life Science?
Nova Mentis Life Science's management team is headed by:
- William Rascan - PRE
- Jamie Robinson - CFO
- Steven Feldman - IND
- Stephen Glazer - IND
- Jacqueline Mcconnell - IND